Abstracts tagged "Parathyroid hormone"

Abstract Number: 0226 • ACR Convergence 2023
Relationships Among Parameters of Mineral Metabolism and Bone Turnover During Acute COVID-related Hospitalization and Subsequent Follow Up: A Pilot Study
Diego Cabrera¹, Clara Wong², Anna Santoro¹, Christine Simpson¹, Karl Insogna¹, Mary Geda¹, Andrew Cohen¹, Alexandra Hadjuk¹, Lauren Ferrante¹ and Evelyn Hsieh³, ¹Yale School of Medicine, New Haven, CT, ²Yale School of Public Health, New Haven, CT, ³Yale University, Department of Medicine, Section of Rheumatology; Yale School of Public Health; Section of Rheumatology, VA Connecticut Healthcare System, Westport, CT
Background/Purpose: Inflammatory conditions can exert direct adverse effects on bone metabolism, via increased bone resorption with inadequate compensatory bone formation. COVID-19 has been associated with…
Abstract Number: 0447 • ACR Convergence 2021
Bone Anabolic Effects of a Novel Orally-Available Small Molecule SIK2/SIK3 Inhibitor
Cheng-Chia Tang¹, Shiv Verma¹, Steve De Vos², David Amantini³, Philippe Clement-Lacroix³, Nicolas Desroy³, Antonio Speziale⁴, Daniel Brooks⁵, Mary Bouxsein⁵, Janaina da Silva Martins¹, Yingshe Zhao⁶, Henry Kronenberg¹ and Marc Wein¹, ¹MGH Endocrine Unit, Boston, MA, ²Galapagos NV, Mechelen, Belgium, ³Galapagos SASU, Romainville, France, ⁴Galapagos GmbH, Basel, Switzerland, ⁵Beth Israel Deaconess Medical Center, Boston, MA, ⁶MGH Endocrine Unnit, Boston, MA
Background/Purpose: Orally-available bone anabolic agents represent a major unmet medical need for patients with osteoporosis. Widespread use of parathyroid hormone (PTH)-based osteo-anabolic therapies is limited…
Abstract Number: 1023 • 2014 ACR/ARHP Annual Meeting
Chronic PTHrP Treatment Promotes Hypertrophic Differentiation and Inflammatory Gene Expression in Chondrocytes
Bin Wang, Center for Translational Medicine, Department of Medicine, Thomas Jefferson University Medical College, Philadelphia, PA
Background/Purpose Parathyroid hormone-related protein (PTHrP) binds to the type 1 PTH receptor (PTH1R), a member of the superfamily of G protein-coupled receptors (GPCRs). Activation of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].